- Home
- LCTX vs LANV Comparison
LCTX vs LANV Comparison
Compare LCTX & LANV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- LANV
- Stock Information
- Founded
- LCTX 1990
- LANV 2015
- Country
- LCTX United States
- LANV China
- Employees
- LCTX N/A
- LANV N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- LANV Blank Checks
- Sector
- LCTX Health Care
- LANV Finance
- Exchange
- LCTX Nasdaq
- LANV Nasdaq
- Market Cap
- LCTX 115.0M
- LANV 196.8M
- IPO Year
- LCTX N/A
- LANV N/A
- Fundamental
- Price
- LCTX $0.50
- LANV $1.70
- Analyst Decision
- LCTX Strong Buy
- LANV
- Analyst Count
- LCTX 4
- LANV 0
- Target Price
- LCTX $4.75
- LANV N/A
- AVG Volume (30 Days)
- LCTX 1.9M
- LANV 23.8K
- Earning Date
- LCTX 11-14-2024
- LANV 08-26-2024
- Dividend Yield
- LCTX N/A
- LANV N/A
- EPS Growth
- LCTX N/A
- LANV N/A
- EPS
- LCTX N/A
- LANV N/A
- Revenue
- LCTX $8,719,000.00
- LANV $409,961,427.00
- Revenue This Year
- LCTX N/A
- LANV N/A
- Revenue Next Year
- LCTX $123.52
- LANV $11.31
- P/E Ratio
- LCTX N/A
- LANV N/A
- Revenue Growth
- LCTX N/A
- LANV N/A
- 52 Week Low
- LCTX $0.50
- LANV $0.91
- 52 Week High
- LCTX $1.61
- LANV $3.99
- Technical
- Relative Strength Index (RSI)
- LCTX 22.34
- LANV 51.89
- Support Level
- LCTX $0.80
- LANV $1.50
- Resistance Level
- LCTX $0.97
- LANV $1.80
- Average True Range (ATR)
- LCTX 0.07
- LANV 0.12
- MACD
- LCTX -0.04
- LANV 0.00
- Stochastic Oscillator
- LCTX 0.70
- LANV 78.49
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.